CELL INTELLIGENCE · 肿瘤细胞治疗研究

用合成细胞因子受体对 T 细胞进行体内工程化改造可实现抗 CD22 CAR-T 细胞的选择性富集和扩增

In vivo engineering of T cells with a synthetic cytokine receptor enables selective enrichment and expansion of anti-CD22 CAR T cells.

嵌合抗原受体的系统性人源化路线图：以人源化 CD22 scFv 为模型的临床前验证

A roadmap for systematic humanization of a chimeric antigen receptor: preclinical validation of a humanized CD22 scFv as a model.

B 细胞恶性肿瘤 CAR-T 细胞治疗后神经毒性的儿童与年轻成人神经影像学发现

Neuroimaging Findings in Children and Young Adults With Neurotoxicity After CAR T-Cell Therapy for B-Cell Malignancies.

ICANS 相关脑 MRI 异常在脑白质、脑干和丘脑中呈现独特模式；其发生率随 ICANS 临床分级升高而增加。

作为 CD22 阳性细胞检测平台的新型 SpyTag 标记模块化纳米抗体的开发与表征

Development and Characterization of A Novel SpyTagged Modular Nanobody as A Detection Platform for CD22-Positive Cells.

本研究制备的新型 FITC-SpyC-SpyT-CD22Nb 能够检测 CD22 的表面表达。

IDR 诱导的 CAR 凝聚增强 CAR-T 对低抗原癌症的细胞毒性

IDR-induced CAR condensation improves the cytotoxicity of CAR-Ts against low-antigen cancers.

EAAAK 连接子增强 CD19/CD22 双特异性 CAR-T 细胞对 B 细胞恶性肿瘤的疗效

Enhanced efficacy of CD19/CD22 bispecific CAR-T cells with EAAAK linker on B-cell malignancies.

本研究构建了一种新型双特异性 CAR-T 细胞，可同时靶向 CD19 或 CD22 阳性肿瘤细胞，为解决单靶点 CAR-T 疗法在 B 细胞肿瘤中的局限性（缓解有限或复发）提供了新策略。

病例报告：CAR-T 细胞治疗受者治疗后发生活动性结核感染——回顾性病例系列

Case Report: Active tuberculosis infection in CAR T-cell recipients post CAR T-cell therapy: a retrospective case series.

靶向两种抗原的 CAR-T 细胞在 B 细胞恶性肿瘤中显示疗效

CAR T Cells Targeting Two Antigens Show Efficacy in B-cell Malignancies.